GlassScriptPhysician profile
Larry Nixon
NPI 1548353683
$2,959.36
in general payments reported to CMS, 2019-2025
22 companies · $1,843 in 2025
The $1,843 reported for 2025 was more than what 97% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $138 · 2020: $85.12 · 2021: $128 · 2022: $23.43 · 2023: $432 · 2024: $310 · 2025: $1,843.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,286 · Travel and Lodging: $1,280 · Education: $18.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,286.37 |
| Travel and Lodging | $1,280.27 |
| Education | $18.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ge Healthcare | $1,443.31 | 2025 | |
| Atricure, INC. | $436.42 | 2023-2025 | Synergy Ablation System, Atricure Cryoice Cryosphere Cryoablation System, Isolator Surgical Ablation System |
| Pacira Pharmaceuticals Incorporated | $154.22 | 2023-2025 | Exparel |
| Acelrx Pharmaceuticals, INC. | $118.74 | 2019 | |
| Potrero Medical, INC. | $100.26 | 2021 | |
| Janssen Pharmaceuticals, INC | $88.75 | 2023-2024 | Xarelto |
| Livanova USA, INC. | $85.12 | 2020 | |
| Draeger Medical Systems, INC | $76.97 | 2025 | Atlan A350 |
| La Jolla Pharmaceutical Company | $61.89 | 2025 | Giapreza |
| Takeda Pharmaceuticals U.S.A., INC. | $59.21 | 2023-2025 | Entyvio |
| Teleflex LLC | $55.39 | 2025 | Arrow, D-Stat |
| Merck Sharp & Dohme LLC | $52.52 | 2023-2024 | Bridion |
| Boston Scientific Corporation | $48.40 | 2022-2025 | Rhythmia Mapping System |
| Abiomed | $31.82 | 2024 | Impella |
| Karl Storz Endoscopy-America | $27.47 | 2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $23.41 | 2024 | Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.72 | 2023 | Xifaxan |
| Integra Lifesciences Corporation | $19.62 | 2021 | |
| Masimo Corporation | $18.94 | 2019 | |
| Ardelyx, INC. | $17.55 | 2025 | Ibsrela |
| Medela LLC | $8.52 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $8.11 | 2024-2025 | Lifevest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Larry Nixon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.